HBIO — Harvard Bioscience, Inc.

Summary of HBIO Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $23.7 million, above guidance of $22.5 million to $24.5 million but down from $24.6 million in Q4 2024.
• Gross Margin: 59.7%, at the high end of guidance and up 260 basis points year-over-year.
• Adjusted EBITDA: $3.8 million, reflecting a 27% increase year-over-year.
• Operating Income: $1.7 million, improved from flat in the previous year; adjusted operating income rose to $3.3 million from $2.5 million.
• Full Year Revenue: $86.6 million, down from $94.1 million in 2024, primarily due to tariffs and delayed NIH funding.
• Full Year Gross Margin: 57.7%, slightly down from 58.2% in 2024.
• GAAP Loss Per Share: Q4 at negative $0.06; full year at negative $1.28, worsened from negative $0.28 in 2024 due to a goodwill impairment.
• Cash Flow from Operations: Improved to $6.7 million from $1.4 million in 2024.
• Net Debt: Decreased to $31.4 million, down $1.8 million from the previous year.

2. Strategic Updates and Business Highlights

• Refinancing: Completed a comprehensive refinancing that extended debt maturity to 2021, reducing annual debt service by $3 million.
• Manufacturing Consolidation: Phased closure of the Holliston facility, expected to generate $3 million in savings in 2027 and $4 million thereafter.
• Governance Improvements: Appointed four new board members and established a Scientific Advisory Board.
• Market Positioning: Transitioning towards being a leader in translational science, with a focus on high-margin product lines and consumables.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected between $20 million and $22 million.
• Full Year 2026 Revenue Growth: Forecasted at 2% to 4%, with adjusted EBITDA growth of 6% to 10%.
• Gross Margin for 2026: Expected between 58% and 60%.
• NPI Growth: Anticipated to drive revenue growth, particularly in high-margin products.

4. Bad News, Challenges, or Points of Concern

• Full Year Revenue Decline: 2025 revenue decreased by 8% year-over-year, attributed to tariffs and NIH funding delays.
• Impact of NIH Funding: Approximately 20% of U.S. revenue is tied to NIH funding, which has been delayed but is expected to improve in Q2 2026.
• GAAP Losses: Significant GAAP losses due to a goodwill impairment, raising concerns about financial health.
• Market Volatility: Ongoing monitoring of NIH funding timing and global macroeconomic conditions, which could impact performance.

5. Notable Q&A Insights

• NIH Funding Impact: Management expects a positive impact from NIH funding approvals towards the end of Q1 and into Q2.
• Product Growth: Key products like BTX and Mesh MEA are expected to see double-digit growth in 2026.
• Asia Pacific Revenue: A rebound in Asia Pacific revenue was noted, with expectations of a return to normalcy barring any new tariff issues.
• Backlog Improvement: The company ended the year with the highest backlog in over two years, indicating potential for future revenue growth.

Overall, while HBIO is navigating challenges related to revenue declines and macroeconomic pressures, strategic initiatives and a focus on high-margin products position the company for potential growth in 2026.